|Mr. Lonnel Coats||Pres, CEO & Director||1.05M||N/A||1965|
|Mr. Jeffrey L. Wade||Exec. VP of Corp. & Admin. Affairs and CFO||610.38k||N/A||1965|
|Dr. Pablo Lapuerta||Exec. VP & Chief Medical Officer||541.51k||N/A||1963|
|Dr. Praveen Tyle||Exec. VP of R&D||487.38k||N/A||1960|
|Mr. Alexander A. Santini||Exec. VP & Chief Commercial Officer||N/A||N/A||1959|
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 7.